Millipore Sigma Vibrant Logo

676495 VEGF Inhibitor, V1 - Calbiochem

The VEGF Inhibitor, V1 controls the biological activity of VEGF. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

VEGF Inhibitor, V1 - Calbiochem: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: ATWLPPR

Primary Target: Specifically competes against VEGF165 binding to recombinant NRP-1
View Products on Sigmaaldrich.com
676495
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

Empirical Formula
C₄₀H₆₁N₁₁O₉

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
676495-1MG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Kst.-Ampulle 1 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewAn NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
      Catalogue Number676495
      Brand Family Calbiochem®
      SynonymsATWLPPR
      References
      ReferencesStarzec, A., et al. 2006. Life Sci. 79, 2370.
      Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.
      Product Information
      ATP CompetitiveN
      FormWhite lyophilized solid
      FormulationSupplied as a trifluoroacetate salt.
      Hill FormulaC₄₀H₆₁N₁₁O₉
      Chemical formulaC₄₀H₆₁N₁₁O₉
      Hygroscopic Hygroscopic
      ReversibleN
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetSpecifically competes against VEGF165 binding to recombinant NRP-1
      Primary Target IC<sub>50</sub>60 µM for specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Peptide SequenceH-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      676495-1MG 04055977260472

      Documentation

      VEGF Inhibitor, V1 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      VEGF Inhibitor, V1 - Calbiochem Analysenzertifikate

      TitelChargennummer
      676495

      Literatur

      Übersicht
      Starzec, A., et al. 2006. Life Sci. 79, 2370.
      Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision10-June-2009 RFH
      SynonymsATWLPPR
      DescriptionAn NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
      FormWhite lyophilized solid
      FormulationSupplied as a trifluoroacetate salt.
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₄₀H₆₁N₁₁O₉
      Peptide SequenceH-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH
      Purity≥95% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesStarzec, A., et al. 2006. Life Sci. 79, 2370.
      Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.